"Naltrexone" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of NALOXONE. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence.
| Descriptor ID |
D009271
|
| MeSH Number(s) |
D03.132.577.249.706.550 D03.605.497.750.550 D03.633.400.686.750.550 D04.615.723.795.706.550
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Naltrexone".
Below are MeSH descriptors whose meaning is more specific than "Naltrexone".
This graph shows the total number of publications written about "Naltrexone" by people in this website by year, and whether "Naltrexone" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 2 | 4 | 6 |
| 1998 | 1 | 0 | 1 |
| 1999 | 2 | 4 | 6 |
| 2000 | 4 | 3 | 7 |
| 2001 | 2 | 2 | 4 |
| 2002 | 1 | 0 | 1 |
| 2003 | 4 | 1 | 5 |
| 2004 | 6 | 0 | 6 |
| 2005 | 3 | 2 | 5 |
| 2006 | 5 | 1 | 6 |
| 2007 | 4 | 4 | 8 |
| 2008 | 9 | 4 | 13 |
| 2010 | 4 | 0 | 4 |
| 2011 | 1 | 2 | 3 |
| 2012 | 4 | 1 | 5 |
| 2013 | 1 | 1 | 2 |
| 2014 | 1 | 3 | 4 |
| 2015 | 2 | 0 | 2 |
| 2016 | 1 | 1 | 2 |
| 2017 | 2 | 0 | 2 |
| 2018 | 3 | 1 | 4 |
| 2019 | 1 | 1 | 2 |
| 2020 | 2 | 2 | 4 |
| 2021 | 2 | 1 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Naltrexone" by people in Profiles.
-
Epigenetic moderators of naltrexone efficacy in reducing heavy drinking in Alcohol Use Disorder: a randomized trial. Pharmacogenomics J. 2022 02; 22(1):1-8.
-
Genetic contributions to alcohol use disorder treatment outcomes: a genome-wide pharmacogenomics study. Neuropsychopharmacology. 2021 11; 46(12):2132-2139.
-
Bupropion and Naltrexone in Methamphetamine Use Disorder. N Engl J Med. 2021 01 14; 384(2):140-153.
-
Non-Opioid Treatments for Opioid Use Disorder: Rationales and Data to Date. Drugs. 2020 Oct; 80(15):1509-1524.
-
Opioid and Dopamine Genes Interact to Predict Naltrexone Response in a Randomized Alcohol Use Disorder Clinical Trial. Alcohol Clin Exp Res. 2020 10; 44(10):2084-2096.
-
World Health Organization risk drinking level reductions are associated with improved functioning and are sustained among patients with mild, moderate and severe alcohol dependence in clinical trials in the United States and United Kingdom. Addiction. 2020 09; 115(9):1668-1680.
-
Systematic review and meta-analysis of the moderating effect of rs1799971 in OPRM1, the mu-opioid receptor gene, on response to naltrexone treatment of alcohol use disorder. Addiction. 2020 08; 115(8):1426-1437.
-
Adherence Across FDA-Approved Medications for Alcohol Use Disorder in a Veterans Administration Population. J Stud Alcohol Drugs. 2019 09; 80(5):572-577.
-
Evaluation of Drinking Risk Levels as Outcomes in Alcohol Pharmacotherapy Trials: A Secondary Analysis of 3 Randomized Clinical Trials. JAMA Psychiatry. 2019 04 01; 76(4):374-381.
-
The uses of naltrexone in dermatologic conditions. J Am Acad Dermatol. 2019 Jun; 80(6):1746-1752.